Emergent BioSolutions

400 Professional Dr
Gaithersburg, MD 20879

Emergent BioSolutions News

Emergent files paperwork for new immuno-oncology spin-off

Friday, May 6, 2016 @ 2:42pm by BioPrepWatch Reports

Emergent BioSolutions announced April 15 that it has begun the formal process of separating some of its assets to form a separate entity, which will be known as Aptevo Therapeutics Inc.
Read More »

Emergent files application to expand production of BioThrax

Wednesday, Apr 27, 2016 @ 11:57am by Khristopher Flack

Emergent BioSolutions has filed a supplemental Biologics License Application with the U.S. Food and Drug Administration to scale up production of its anthrax vaccine BioThrax.
Read More »

DoD tests platform for nerve agent antidote

Friday, Feb 19, 2016 @ 6:01pm by BioPrepWatch Reports

The U.S. Department of Defense (DoD) has selected Emergard as a potential candidate for a nerve agent antidote delivery system.
Read More »

Emergent introduces spin-off's board of directors

Thursday, Dec 24, 2015 @ 5:05pm by BioPrepWatch Reports

Emergent Biosolutions has announced the selection of its spin-off company’s board of directors.
Read More »

Emergent receives therapeutic supply contract from CDC

Friday, Aug 14, 2015 @ 4:25pm by BioPrepWatch Reports

Emergent BioSolutions has received a $44 million contract from the Centers for Disease Control and Prevention (CDC) to supply Vaccinia Immune Globulin Intravenous (VIGIV) therapeutic treatments, the company announced Thursday.
Read More »

Emergent to spin off oncological and hematological therapeutics development

Thursday, Aug 6, 2015 @ 3:57pm by BioPrepWatch Reports

Emergent BioSolutions, Inc. announced on Thursday that it intends to spin off a portion of the company into a separate publicly traded company. The new company will largely focus on oncological and hematological therapeutics development. Emergent will retain products and development programs specifically for the biological defense markets.
Read More »

Emergent announces launch of Emergard military-grade auto-injector

Monday, Aug 3, 2015 @ 2:51pm by BioPrepWatch Reports

Emergent BioSolutions has launched a military-grade auto-injection device, Emergard, which is able to manage self-injections of antidotes and other countermeasures against chemical and related threats, the company announced on Monday.
Read More »

Emergent awarded $19.7 million Barda contract

Monday, Jul 20, 2015 @ 7:54pm by BioPrepWatch Reports

Company will develop monoclonal antibodies of Ebola
Read More »

Emergent: New BioThrax facility meets standards

Friday, Feb 13, 2015 @ 2:59pm by BioPrepWatch Reports

An efficacy study on Emergent BioSolutions' new BioThrax production facility has concluded that production was comparable to an already approved facility, the company said on Friday.
Read More »

Emergent BioSolutions seeking expanded label for anthrax vaccine

Tuesday, Nov 11, 2014 @ 12:23pm by BioPrepWatch Reports

Emergent BioSolutions Inc. is asking the U.S. Food and Drug Administration (FDA) to allow it to include a post-exposure prophylaxis (PEP) indication on its BioThrax label, the company announced on Monday.
Read More »

Emergent BioSolutions testing could lead to tripling of BioThrax manufacturing capacity

Tuesday, Sep 23, 2014 @ 10:54am by BioPrepWatch Reports

Emergent BioSolutions Inc. announced on Tuesday it will start a new non-clinical efficacy study to demonstrate that BioThrax manufactured at its new plant in Lansing, Michigan, is comparable to the same product produced at its smaller-capacity facility.
Read More »